Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
133 tokens/sec
GPT-4o
7 tokens/sec
Gemini 2.5 Pro Pro
46 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
38 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities (2403.17117v1)

Published 25 Mar 2024 in stat.ME

Abstract: In confirmatory clinical trials, survival outcomes are frequently studied and interim analyses for efficacy and/or futility are often desirable. Methods such as the log rank test and Cox regression model are commonly used to compare treatments in this setting. They rely on a proportional hazards (PH) assumption and are subject to type I error rate inflation and loss of power when PH are violated. Such violations may be expected a priori, particularly when the mechanisms of treatments differ such as immunotherapy vs. chemotherapy for treating cancer. We develop group sequential tests for comparing survival curves with covariate adjustment that allow for interim analyses in the presence of non-PH and offer easily interpreted, clinically meaningful summary measures of the treatment effect. The joint distribution of repeatedly computed test statistics converges to the canonical joint distribution with a Markov structure. The asymptotic distribution of the test statistics allows marginal comparisons of survival probabilities at multiple fixed time points and facilitates both critical value specification to maintain type I error control and sample size/power determination. Simulations demonstrate that the achieved type I error rate and power of the proposed tests meet targeted levels and are robust to the PH assumption and covariate influence. The proposed tests are illustrated using a clinical trial dataset from the Blood and Marrow Transplant Clinical Trials Network 1101 trial.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (35)
  1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Eng J Med, 373(17):1627–1639.
  2. Breslow, N. (1974). Covariance analysis of censored survival data. Biometrics, pages 89–99.
  3. Chen, T.-T. (2013). Statistical issues and challenges in immuno-oncology. J Immunother Cancer, 1(1):1–9.
  4. Covariate imbalance and adjustment for logistic regression analysis of clinical trial data. J Biopharm Stat, 23(6):1383–1402.
  5. Continuous covariate imbalance and conditional power for clinical trial interim analyses. Contemp Clin Trials, 38(1):9–18.
  6. Cox, D. R. (1972). Regression models and life-tables. J R Stat Soc Series B Stat Methodol, 34(2):187–202.
  7. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis, 10(Suppl 13):S1564.
  8. Counting processes and survival analysis. John Wiley & Sons.
  9. Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). Blood.
  10. Variance calculations for direct adjusted survival curves, with applications to testing for no treatment effect. Biom J, 28(5):587–599.
  11. Hoos, A. (2012). Evolution of end points for cancer immunotherapy trials. Ann Oncol, 23:viii47–viii52.
  12. Assessing differences in clinical trials comparing surgical vs nonsurgical therapy: using common (statistical) sense. JAMA, 278(17):1432–1436.
  13. Group sequential methods with applications to clinical trials. CRC Press.
  14. The statistical analysis of failure time data. John Wiley & Sons.
  15. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Eng J Med, 363(5):411–422.
  16. Discrete sequential boundaries for clinical trials. Biometrika, 70(3):659–663.
  17. Group sequential designs for monitoring survival probabilities. Biometrics, 52(3):1033–1041.
  18. Group sequential tests for long-term survival comparisons. Lifetime data analysis, 21:218–240.
  19. Mantel, N. (1972). Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemother Rep, 50:187–220.
  20. Sequential methods for comparing years of life saved in the two-sample censored data problem. Biometrics, 55(4):1085–1092.
  21. A multiple testing procedure for clinical trials. Biometrics, pages 549–556.
  22. Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. Biometrika, 64(2):191–199.
  23. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Statistics in medicine, 21(19):2917–2930.
  24. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC medical research methodology, 13(1):1–15.
  25. Understanding and communicating measures of treatment effect on survival: can we do better? JNCI: Journal of the National Cancer Institute, 110(3):232–240.
  26. Semiparametric efficiency and its implication on the design and analysis of group-sequential studies. Journal of the American Statistical Association, 92(440):1342–1350.
  27. Sequential analysis of the proportional hazards model. Biometrika, 70(2):315–326.
  28. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. Biometrics, 74(2):694–702.
  29. Todd, S. (2007). A 25-year review of sequential methodology in clinical studies. Statistics in medicine, 26(2):237–252.
  30. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA, 317(23):2392–2401.
  31. Yang, S. (2019). Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes. Statistics in Medicine, 38(4):601–612.
  32. Efficient estimation of semiparametric transformation models for counting processes. Biometrika, 93(3):627–640.
  33. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed, 88(2):95–101.
  34. Quantifying treatment effects using the personalized chance of longer survival. Statistics in medicine, 38(28):5317–5331.
  35. Zucker, D. M. (1998). Restricted mean life with covariates: modification and extension of a useful survival analysis method. J Am Stat Assoc, 93(442):702–709.

Summary

We haven't generated a summary for this paper yet.

X Twitter Logo Streamline Icon: https://streamlinehq.com